FEATURED TRIALS
Acute Migraine
A Study to Evaluate the Efficacy and Safety of BHV-2100 in Migraine
Drug: BHV-2100
Age: 18-64
Phase: 2
Generalized Epilepsy
Researching an Investigational Treatment Option for Idiopathic Generalized Epilepsy
Drug: BHV-7000
Age: 18-75
Phase: 3
FOCAL EPILEPSY
Researching an investigational treatment option for Focal Onset Epilepsy
Drug: BHV-7000
Age: 18-75
Phase: 2/3
Major Depressive Disorder
A Study to Evaluate the Efficacy and Safety of BHV-7000 Monotherapy in Major Depressive Disorder
Drug: BHV-7000
Age: 18-75
Phase: 2
Bipolar Disorder I
An Inpatient Study to Evaluate the Effectiveness and Safety of BHV-7000 for Manic Episodes Associated with Bipolar I Disorder
Drug: BHV-7000
Age: 18-75
Phase: 2/3
Obsessive Compulsive Disorder (OCD)
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Drug: Troriluzole
Age: 18-65
Phase: 3
OUR FAMILY IS WORKING HARD FOR YOU
Biohaven is a clinical-stage pharmaceutical company.
Throughout his career as a practicing physician, Associate Clinical Professor of Psychiatry and as Biohaven’s Chairman and CEO, Dr. Vlad Coric is dedicated to advancing treatment for brain disorders and other rare and common diseases.
Clinical trials can transform lives.
Finding new treatments that improve people’s health and change lives involves rigorous study in clinical trials before they are approved for use. Being part of a clinical trial has the potential to not only improve the lives of participants, but the lives of others as well.
WE ARE SOCIAL
